Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PDCO, MYGN, BMRN - Hot Stocks at NASDAQ Healthcare Sector by

Patterson Companies, Inc. (NASDAQ:PDCO) decreased 0.07% to close at $29.04. PDCO traded 1.54 million shares for the day and its earning per share remained $1.85. Patterson Companies, Inc. (Patterson) is a distributor serving three markets: North American dental supply, U.S. companion-pet (dogs, cats and other common household pets) and equine veterinary supply, and the global rehabilitation and assistive products supply market. The Company operates in three segments: dental supply, veterinary supply and rehabilitation supply. Patterson Logistics Services, Inc., Accu-Bite, Inc., Accu-Bite Products Limited Liability Company and Williamston Industrial Center, LLC.

Myriad Genetics, Inc. (NASDAQ:MYGN) increased 3.39% to close at $21.96. MYGN traded 1.49 million shares for the day and its earning per share remained $1.47. Myriad Genetics, Inc. is a molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine products. The molecular diagnostic products are designed to analyze genes and their mutations to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence, and measure a patient's exposure to drug therapy to ensure optimal dosing and reduced drug toxicity.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) decreased 0.85% to close at $26.72. BMRN traded 1.40 million shares for the day and its earning per share remained $1.88. BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio consists of four approved products and multiple investigational product candidates. In January 2010, it initiated a Phase I trial of its small molecule for the treatment of Duchenne muscular dystrophy. In August 2010, BioMarin acquired ZyStor Therapeutics, Inc.


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Disclosure: No positions